Outbreak of corona virus : All you need to know


Journal of Clinical Immunology and Allergy is a world class open access journal intended to publish the cutting-edge research in the field of Immunology and Allergy.

The Journal endeavours to publish both basic, fundamental and advanced developmental research in Allergy and immunology involves the management of disorders related to the immune system.

What is a coronavirus strain?

The virus belongs in the same family of coronaviruses as Severe Acute Respiratory Syndrome (SARS). The virus strain was 80% genetically identical to SARS. Its symptoms include fever and difficulty in breathing, which are similar to many other respiratory diseases and poses complications for screening efforts. The outbreak of the disease is a never-before-seen strain belonging to a broad family of viruses ranging from the common cold to more serious illnesses such as SARS. The new strain is the seventh known type of coronavirus that humans can contract.

Viral interactions with the innate immune system play a central role in determining the outcome of infection. Early control of viral replication by type I Interferons (IFN), complement proteins, and other innate immune mediators limit viral spread within the host during the early phases of the disease.

The early innate response also plays an important role in shaping the downstream adaptive immune response, however an overactive innate immune response can also result in immune pathology and subsequent tissue damage. 

Coronavirus interactions with the adaptive immune system have been studied in detail, however, surprisingly little is known about how these viruses interact with the innate immune system. Although early studies indicated that mutations in the M glycoprotein of transmissible gastroenteritis virus (TGEV) modulated type I IFN responses, suggesting that coronaviruses may encode a novel set of gene functions that interface with the host innate immune response, little effort focused on unraveling the details of coronavirus innate immune interactions.

How did the virus spread?

Chinese authorities are still not sure of the origin of the virus. The source may have been animals sold at the market and from there it passed to the human population. Authorities have pronounced the risk of human transmission "weak" but not impossible. Chinese officials claimed that with the implementation of our various prevention and control measures, the epidemic can be prevented and controlled.

Why is the virus dangerous?

It belongs to the family of the SARS virus, which killed nearly 800 people globally during a 2002/03 outbreak that also started in China. Though some experts say the new virus may not be as deadly as SARS, there is still little known about it including its origin and how easily it can be transmitted between humans.

What are the efforts being made to contain the virus?

At least a half-dozen countries in Asia and three US airport have started screening incoming airline passengers from central China. Shares in pharmaceutical firms and mask makers in China surged Monday because of the outbreak.

Journal accepts original manuscripts in the form of research articles, review articles, Clinical reviews, commentaries, case reports, perspectives and short communications encompassing all aspects of Clinical Immunology and Allergy for publication in open access platform.

All the manuscript published by Clinical Immunology and Allergy are available freely online immediately after publication without any subscription charges or registration.
• After submission, an acknowledgement with manuscript number is sent to the corresponding author within 7 working days.
• A 21-day window time frame is allotted for peer-review process wherein multiple experts are contacted.
• Author proof is generated within 7 working days after the acceptance decision.

Manuscripts can be submitted at: http://www.imedpub.com/submissions/insights-allergy-asthma-bronchitis.html or can be submitted as an attachment to this E-mail: clinicalimmuno@clinicalmedicaljournals.com

Open Access: Permanent free access to your article upon publication ensures extensive global reach and readership.

Global Marketing: Through promotion in a targeted global email announcement or press release, your article will be seen by thousands of the top-most thought-leaders in your field.

Social Media Exposure: Extended reach for your article through links on Twitter accounts provides maximum visibility worldwide.

Media Contact
Sana George
Journal Manager
Clinical Immunology and Allergy
Email: clinicalimmuno@clinicalmedicaljournals.com
WhatsApp: +1-947-333-4405